Navigation Links
Monogram Announces Commercial Availability of the HERmark(TM) Breast Cancer Assay
Date:7/8/2008

monogrambio.com.

Forward Looking Statements

Certain statements in this press release are forward-looking. These forward-looking statements include references to the ability of the HERmark assay to predict response to Herceptin or to significantly improve the information available to physicians, results of studies intended to demonstrate clinical utility of HERmark, and successful commercialization of the HERmark assay or other VeraTag assays. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties relating to the performance of our products, including HERmark; the risk that our VeraTag assays, including HERmark may not predict response to Herceptin or other therapeutic agents; the risk that we may not be able to obtain additional cohorts of patient samples for additional HERmark or VeraTag studies; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; actual market acceptance of our products for patient use and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
2. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
3. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
4. Monogram Announces First Medicare Payment for Trofile(TM)
5. The Center for Professional Innovation and Education (CfPIE) Announces the First True Certification Program for Document Management Professionals in the Life Sciences
6. The Center for Professional Innovation and Education (CfPIE) Announces a New Global Regulatory Certification Track
7. GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems
8. NHP Announces Second Quarter Earnings Release Date and Conference Call/Webcast
9. Ventas Announces 2008 Second Quarter Earnings Release Date and Conference Call
10. QuikByte Software, Inc. Announces Changes to Board of Directors and Executive Ranks
11. March of Dimes Announces Nursing Scholarship Recipients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)...vides for an unprecedented expansion of federally-...s not for preserving and protecting human life? If...harmaine Yoest ,, WASHINGTON, Nov. 21 /PRNews...on President and CEO Dr. Charmaine Yoest responded...following statement: ,, "This was a pro-aborti...
(Date:11/21/2009)... 21, 2009 Test Test Test... Test Test Test Test Test Test,Test Test Test Test... Test,Test Test Test Test Test Test Test Test Test...e test More test More test More test More test,Mor...e test More test More,test More test , , Pleas...
(Date:11/21/2009)... J. Hall, president and chief executive officer of...d the following statement regarding the inclusion ...ew annual wellness for Medicare beneficiaries in &...t" that was introduced last night: , ... 2009 -- Eric J. Hall, president and chief executi...
(Date:11/20/2009).... 20 /PRNewswire-FirstCall/ - NUCRYST Pharmaceutic...f Shareholders will be held on Monday, December 21...approval of two special resolutions. The first spe...le of all or substantially all of the assets of NU...the asset purchase agreement dated November 10, 20...
(Date:11/20/2009)...tors and Congressmen in Competitive Re-election Ba...ote , Washington, DC (Voc...running for re-election next year in races deemed ...may come to regret voting for House Speaker Nancy ...eaking Zogby International/ O’Leary Report ...
Breaking Medicine News(10 mins):Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3
...ustry a panel comprising European experts recommen... approved for sales// in the European Union. This ... The action of the pill Acomplia (rimonabant) is...a trial involving more than 6,600 patients worldwi...
...ge of Nursing congress last week shouted at Patric...e become unnerving, demonstrating// their hostilit...ear ago. But the question is why and what are the.... Les Miles worked in the neo-natal department as ...
...hicago reporting in the May issue of the journal M...ve that it is alright to discuss religion with the...tors encourage patients to speak about their belie...iefs and experiences to patients. Fewer than one o...
... be enough shine, making Washington, a hot spot fo...ding to the Environmental// Protection Agency. ...nabling free kits to schools that comprise of 40 a...skin lotions on the frisbee’s white disc, and this...
...to occur in children whose mothers report difficul...ental health, one year after delivery, reports a s...ry. // The presence of anxiety / mood disord...ems in children. Although previous studies have sh...
...labama households. But it accounts for about 10% o... to 14 years. //A survey was conducted which showe...dge about the household firearms. The survey resul..., 3 children are injured by guns but do not die. ...
Other Medicine News:Health News:Doctors' Response To Patients' Religious Beliefs Can Vary 2Health News:Doctors' Response To Patients' Religious Beliefs Can Vary 3Health News:Maternal Difficulties Increase Risk of Behavior Problems in Children 2Health News:Parents Unaware of their Children’s Knowledge about Household Firearm 2
(Date:11/20/2009)...ire/ -- ,, Reportlinker.com announces that a ne...ogue. ,, Global Markets for Breast Biopsy Devi...4741/Global-Markets-for-Breast-Biopsy-Devices-2009...utm_campaign=prnewswire ,, The global markets...ded core needle market and vacuum assisted breast ...
(Date:11/20/2009)...-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX ) t... Executive Officer, and Greg Browne, Chief Financi...Jaffray Health Care Conference in New York on Wedn...erence session and webcast will be audio only and ... will host a webcast of the presentation live and ...
(Date:11/19/2009)...swire/ -- Warner Chilcott plc (Nasdaq: WCRX ) tod...ed secondary offering of 20,000,000 of its ordinar...are. The selling shareholders include funds affil...king, J.P. Morgan Partners (advised by CCMP Capita... institutional investors and members of the Compan...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Neuronascent to Present at Life Sciences Summit 2009 14061 1Neuronascent to Present at Life Sciences Summit 2009 14061 2Filmmaker John Hughes 26apos 3B Recent Untimely Death is a Call for Better Understanding 0Aof Sudden Cardiac Death the Leading Cause of Natural Deat 57200 1Filmmaker John Hughes 26apos 3B Recent Untimely Death is a Call for Better Understanding 0Aof Sudden Cardiac Death the Leading Cause of Natural Deat 57200 2Filmmaker John Hughes 26apos 3B Recent Untimely Death is a Call for Better Understanding 0Aof Sudden Cardiac Death the Leading Cause of Natural Deat 57200 3Filmmaker John Hughes 26apos 3B Recent Untimely Death is a Call for Better Understanding 0Aof Sudden Cardiac Death the Leading Cause of Natural Deat 57200 4Filmmaker John Hughes 26apos 3B Recent Untimely Death is a Call for Better Understanding 0Aof Sudden Cardiac Death the Leading Cause of Natural Deat 57200 5Filmmaker John Hughes 26apos 3B Recent Untimely Death is a Call for Better Understanding 0Aof Sudden Cardiac Death the Leading Cause of Natural Deat 57200 6Milliman Report Addresses the Potential Impact of Height and Weight on Medical Costs 57198 1Milliman Report Addresses the Potential Impact of Height and Weight on Medical Costs 57198 2
...novio Biomedical’s DNA Delivery Technology,S...te Cancer,Vaccine , ,Key Milestone for First-in-Ma...Electroporation DNA Delivery Technology , , ,SAN D...X: INO),focused on the development of DNA-based v...novel alternative to surgery to treat,localized ca...
...ARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Prin...mium STent with,Antiproliferative for Restenosis) ...chromium paclitaxel-eluting coronary stent,presen...at EuroPCR,2007. The investigators confirmed that ...or previously announced this conclusion in a,press...
Other Medicine Technology:Inovio: DNA delivery technology shows positive human results 2Inovio: DNA delivery technology shows positive human results 3Inovio: DNA delivery technology shows positive human results 4Inovio: DNA delivery technology shows positive human results 5Inovio: DNA delivery technology shows positive human results 6Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial,Results at EuroPCR 2007 2Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial,Results at EuroPCR 2007 3
Storz Tying Forceps
Storz Straight Tying Forceps
Sheets-Kelman-McPherson Forceps
Tying Forceps - Straight
Medicine Products: